Marker Therapeutics, Inc.

Monthly Archives: January 2016

TapImmune Appoints Frederick G. Wasserman to its Board of Directors

TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, is pleased to announce the appointment of Frederick G.
Read More

TapImmune to Present at Biotech Showcase 2016 in San Francisco on January 11, 2016

https://www.markertherapeutics.com/wp-content/uploads/2016/01/Biotech-Showcase-2016.png JACKSONVILLE, FLORIDA, January 7 , 2015 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer &
Read More